XML 45 R35.htm IDEA: XBRL DOCUMENT v3.25.1
Collaboration Agreements, License Agreement and Revenues - Astellas Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended
Apr. 30, 2006
Jun. 30, 2005
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue     $ 2,739,000 $ 25,364,000  
Deferred Revenue     22,509,000   $ 27,290,000
Drug Product Revenue, Net [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue     2,595,000 24,486,000  
Japan [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Transaction price, variable consideration from estimated future co-development billing     0    
Europe [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Transaction price, variable consideration from estimated future co-development billing     $ 0    
Astellas Agreement [Member] | Japan [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Upfront, non-contingent and time-based payments received   $ 172,600,000      
Additional consideration based on net sales description     the low 20% range of the list price    
Aggregate consideration received excluding drug product revenue     $ 105,100,000    
Transaction price, variable consideration from estimated future co-development billing     0 0  
Changes in revenue from changes to estimated variable consideration     0    
Astellas Agreement [Member] | Japan [Member] | License [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Cash Consideration Received Under Collaboration Agreement     100,300,000    
Astellas Agreement [Member] | Japan [Member] | Co-development, information sharing & committee services [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Cash Consideration Received Under Collaboration Agreement     $ 17,100,000    
Astellas Agreement [Member] | Europe [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Upfront, non-contingent and time-based payments received $ 745,000,000        
Additional consideration based on net sales description     low 20% range    
Aggregate consideration received excluding drug product revenue     $ 685,000,000    
Percentage of joint development costs committed to fund 50.00%        
Changes in revenue from changes to estimated variable consideration     0    
Astellas Agreement [Member] | Europe [Member] | License [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue     0 $ 0  
Cash Consideration Received Under Collaboration Agreement     619,000,000    
Astellas Agreement [Member] | Europe [Member] | Co-development, information sharing & committee services [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Cash Consideration Received Under Collaboration Agreement     $ 288,300,000